GAUCHER DISEASE, TYPE 1
Clinical trials for GAUCHER DISEASE, TYPE 1 explained in plain language.
Never miss a new study
Get alerted when new GAUCHER DISEASE, TYPE 1 trials appear
Sign up with your email to follow new studies for GAUCHER DISEASE, TYPE 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare disease: first human test of FLT201 begins
Disease control CompletedThis early-stage study tested a new drug, FLT201, in 6 adults with Gaucher disease type 1. The main goal was to check safety and how well the body tolerates the drug. Researchers also looked at whether FLT201 can boost the missing enzyme and reduce harmful buildup in cells.
Matched conditions: GAUCHER DISEASE, TYPE 1
Phase: PHASE1 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Gaucher disease study probes brain chemistry clues
Knowledge-focused CompletedThis study looked at levels of certain brain chemicals linked to oxidative stress and inflammation in people with Type 1 Gaucher disease and healthy volunteers. Researchers used brain scans to measure these chemicals over time. The goal was to understand how Gaucher disease affec…
Matched conditions: GAUCHER DISEASE, TYPE 1
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated May 04, 2026 16:19 UTC